We randomly allocated patients ( @:@ ; with a computer-generated unicentric randomisation list -LSB- prepared by the study funder -RSB- and interactive voice response system ; block size of six ; stratified by metastatic site -LSB- single vs multiple organs -RSB- and time from diagnosis of metastatic disease -LSB- < @ months vs @ months -RSB- ) to receive oral regorafenib @ mg once daily or placebo on days @-@ of each @ day cycle ; patients in both groups were also to receive best supportive care .